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We conducted a study to evaluate arterial stiffness markers in subjects with acute ischemic stroke and
metabolic syndrome and in relation to TOAST subtype of stroke. We enrolled 130 patients with acute
ischemic stroke and metabolic syndrome, 127 patients with acute ischemic stroke without metabolic
syndrome and 120 control subjects without acute stroke. Applanation tonometry to record pulse wave
velocity (PWV). Stroke patients with metabolic syndrome, compared control subjects without stroke
showed higher PWV. In subjects with ischemic stroke and metabolic syndrome, PWV was more signiﬁ-
cantly and positively correlated with body mass index, systolic blood pressure, hypertension, diabetes,
glucose blood levels, LDL cholesterol levels, total cholesterol levels, micro-albuminuria, carotid plaque,
previous brain infarct at neuro-imaging. Our ﬁndings underline important role of both small vessel disease
and atherosclerosis on arterial stiffness pathogenesis in the clinical setting of metabolic syndrome.
 2012 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Metabolic syndrome (MetS) [1] and arterial stiffness [2] are
recognized risk factors for ischemic stroke [3e5].
Nevertheless, no study has evaluated the relationship between
arterial stiffness and ischemic stroke in patients with metabolic
syndrome. On this basis we conducted a study to evaluate arterial
stiffness markers in subjects with acute ischemic stroke and
metabolic syndrome, and to evaluate the relationship between
these indexes and other clinical and laboratory variables and each
component of metabolic syndrome.
2. Materials and methods
2.1. Patient selection
Patients were considered as having metabolic syndrome on
a basis of modiﬁcation of the NCEP/ATP III [6].
We enrolled all consecutive patients with a diagnosis of acute
ischemic stroke admitted to the Internal Medicine Department at
the University of Palermo between November 2009 and January
2011. As controls, we used hospitalized patients with acute
ischemic stroke without a diagnosis of metabolic syndrome, and
hospitalized patients without a diagnosis of acute ischemic stroke,
admitted, in the same period, to our Internal Medicine Department
for any cause other than acute cardiovascular and cerebrovascular
events.
Stroke was deﬁned by focal neurological signs or symptoms
thought to be of vascular origin that persisted for >24 h, conﬁrmed
by brain CT and/or MRI in baseline conditions and brain CT with
contrast medium after 48e72 h [7].
Cardiovascular risk factors were evaluated for both cases and
controls on the basis of the criteria as shown in Supplemental
Material.
The type of acute ischemic strokewas classiﬁed according to the
TOAST classiﬁcation [8]:
1) Large Artery AtheroSclerosis (LAAS); 2) Cardio-Embolic
Infarct (CEI); 3) LACunar infarct (LAC); 4) stroke of Other Deter-
mined Etiology (ODE); 5) stroke of UnDetermined Etiology.
2.2. PWV measurement
Carotid-femoral PWV was measured in the supine position
using the automatic device (SphygmoCor version 7.1) that
measured the time delay between the rapid upstroke of the carotid
and femoral artery pulsewaves. PWVwas calculated as the distance
traveled by the arterial pulse wave (meters) divided by the time
delay between the 2 arterial points (seconds), thus expressed as
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meters per second. Three data collection runs were performed,
each obtaining a minimum of 10 pairs of simultaneously recorded
ﬂow waves. The “distance between the 2 arterial points” was
measured using the total distance between the carotid and femoral
sites of measurement.
2.3. Pulse wave analysis
The aortic pressure waveform was used to calculate the AIx
(difference in height between the ﬁrst and second systolic peaks
expressed as a percentage of PP).
2.4. Statistical analysis
Data are expressed as the mean  SD. All data were analyzed
using the SAS 9.1 statistical program. Clinical characteristics were
compared among the four groups using a one-way ANOVA. Pear-
son’s correlation coefﬁcients were calculated to evaluate the rela-
tionship of PWV with cardiovascular risk factors in all stroke
patients and in each TOAST subtype. Signiﬁcancewas deﬁned at the
0.05 conﬁdence level.
3. Results
We enrolled 130 patients with acute ischemic stroke and
metabolic syndrome, 127 patients with acute ischemic stroke
without metabolic syndrome and 120 control subjects matched for
age, sex, cardiovascular risk factors and previous cardiovascular
morbidity.
Baseline characteristics in stroke patients and in relation to each
TOAST subtype are given in Tables 1 and 2.
Stroke patients with metabolic syndrome, compared to subjects
without metabolic syndrome and with stroke, and compared to
control subjects without stroke showed a higher mean PWV
(12.9  3.3 m/s vs. 11.2  2.8 m/s vs. 10.02  2.29 m/s; p < 0.001).
PWV values in lacunar subjects with metabolic syndrome
were signiﬁcantly higher compared to values observed in
subjects with lacunar stroke without metabolic syndrome
(14.45  2.6 m/s vs. 12.81  2.1 m/s). PWV in subjects with
LAAS and metabolic syndrome were signiﬁcantly higher
compared to values observed in subjects with LAAS stroke
without metabolic syndrome (11.2  2.31 m/s vs. 10.4  2.22 m/
s) and PWV in subjects with CEI subtype and metabolic
syndrome were signiﬁcantly higher compared to values observed
in subjects with CEI subtype without metabolic syndrome
(11.48  1.98 m/s vs. 10.7  3.5).
3.1. Relationship between PWV and clinical and laboratory
variables in stroke patients
In subjects with ischemic stroke and metabolic syndrome,
compared to those with ischemic stroke and without metabolic
syndrome, pulse wave velocity (PWV) was more signiﬁcantly and
positively correlated with body mass index (BMI) (r ¼ 0.44 vs 0.39;
p ¼ 0.021), SBP (r ¼ 0.42 vs 0.38; p ¼ 0.040), hypertension (r ¼ 0.42
vs 0.36; p < 0.05), diabetes (r ¼ 0.44 vs 0.38; <0.05), glucose blood
levels(r ¼ 0.44 vs 0.31; p < 0.05), LDL cholesterol levels(r ¼ 0.36 vs
0.30; p¼ 0.011), total cholesterol levels (r¼ 0.38 vs 0.31; p¼ 0.010),
CAD (r ¼ 0.37 vs 0. 29; p ¼ 0.022), micro-albuminuria(r ¼ 0.40 vs
0.30; p< 0.05), carotid plaque (r¼ 0.35 vs 0.29; p¼ 0.030), previous
brain infarct at neuro-imaging(r ¼ 0.33 vs 0.28; p ¼ 0.040),
WMHLS(r ¼ 0.32 vs 0.24; p < 0.05).
Table 1
Premorbid cardiovascular risk factors, clinical characteristics and medication.
Variable Stroke pts with metabolic
syndrome (n:130)
Stroke pts without metabolic
syndrome (n:127)
Controls (n:109) P
Age (years) 64 (61e72.5) 72 (69e83.5) 69 (63e80) 0.031
M/F (n) 69/61 60/67 54/55 0.027
SBP/DBP (mm/Hg) 152  7.9/98  6.2 147  8.9/92  3.2 141  9.8/91  2.2 <0.001
diabetes (n/%) 63 (48.46) 39 (30%) 47 (41.28%) 0.263
Hypertension (n/%) 66 (50.79%) 47 (37%) 48 (44.03%) 0.301
Glucose blood levels (mg/dl) 149.3 (97e186) 129.1 (88e142) 102 (81.5e133.5) <0.001
Cholesterol blood levels (mg/dl) 241 (189e270) 222 (179e245) 210 (167e225) <0.001
Triglyceride blood levels (mg/dl) 197.5 (149.75e210.75) 157.5 (119.4e181.75) 167.5 (139.4e192.1) 0.004
White blood cells (per mm3) 9100 (6200e11,000) 8200 (7100e10,500) 7400 (6500e9800) <0.001
Stroke subtype
LAAS 49 (37.69) 52 (40.94)
Lacunar 45 (34.61) 37 (29.7)
CEI 32 (24.61) 35 (27.55)
ODE 3 (2.3) 2 (1.57)
UDE 1 (0.76) 1 (0.78)
AIx (%) 105  3.5 101  4.1 89  4.6 <0.001
PWV (m/s) 12.9  3.3 11.2  2.8 10.02  2.29 <0.001
SSS 27.12  16.21 29.35  16.21 30  16.21
NIHSS 19.41  10.06 21.21  90.06 e
Ms-Rankin score at discharge
I 25 (18.23) 32 (25.19)
II 23 (17.69) 31 (24.40)
III 32 (24.61) 28 (22.04)
IV 29 (22.30) 23 (18.11)
V 21 (16.15) 13 (10.23)
Exitus (n/%) 17 (13.07) 11 (8.66) e <0.001
CAD (n/%) 42 (32.23) 37 (29.13) 37 (36.27) 0.44
CHF (n/%) 23 (17.69) 20 (15.74) 15 (14.70) 0.065
SBP: systolic blood pressure; DBP: diastolic blood pressure; MAP: mean arterial pressure; AIx: augmentation index; PWV: pulse wave velocity; SSS: Scandinavian Stroke Scale
score; NIHSS: National Institutes of Health Stroke Scale; Angiotensin II receptor blockers (ARBs); CAD: coronary artery disease; CHF: congestive heart failure; TIA: transitory
ischemic attack; LVH: left ventricular hypertrophy; WMHLS: white matter hypertension lesions.
Demographic and history data are expressed as n (percentage).
In bold are expressed values of p < 0.05.
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3.2. Relationship between PWV and clinical and laboratory
variables in stroke patients in relation to each TOAST subtype
Among subjects with Lacunar subtype, those with metabolic
syndrome, compared to those without metabolic syndrome,
showed a more signiﬁcant positive correlation between PWV and
Age (r ¼ 0.40 vs 0.33; p ¼ 0.025), SBP(r ¼ 0.37 vs 0.29; p ¼ 0.022),
hypertension (r ¼ 0.42 vs 0.34; p < 0.05), diabetes(r ¼ 0.43 vs 0.34;
p < 0.05), previous stroke (r ¼ 0.37 vs 0.29; p ¼ 0.022), glucose
blood levels (r ¼ 0.38 vs 0.31; p ¼ 0.021), micro-albuminuria
(r ¼ 0.39 vs 0.29; p < 0.05), carotid plaque (r ¼ 0.41 vs 0.34;
p ¼ 0.031), LVH (r ¼ 0.35 vs 0.29; p ¼ 0.033), and previous brain
infarct at neuro-imaging (r ¼ 0.35 vs 0.28; p ¼ 0.027), WMHLS
(r ¼ 0.35 vs 0.24; p ¼ 0.025).
Among LAAS subtype, stroke patients with metabolic syndrome
compared to those without metabolic syndrome, showed a more
signiﬁcant positive correlation between PWV and SBP (r ¼ 0.38 vs
0.27; p ¼ 0.040), hypertension (r ¼ 0.40 vs 0.34; p ¼ 0.023), LDL
cholesterol plasma levels (r ¼ 0.40 vs 0.30; p < 0.05), total
cholesterol plasma levels (r ¼ 0.39 vs 0.30 p ¼ 0.012), CAD (r ¼ 0.29
vs 0.23; p ¼ 0.040), CHF (r ¼ 0.21 vs 0.19; p ¼ 0.022), carotid plaque
(r ¼ 0.38 vs 0.32; p ¼ 0.028), LVH (r ¼ 0.37 vs 0.29; p ¼ 0.022), and
previous brain infarct at neuro-imaging (r ¼ 0.37 vs 0.30;
p ¼ 0.037).
Among CEI subjects, stroke patients with metabolic syndrome
compared to those without metabolic syndrome, showed a more
signiﬁcant positive correlation between PWV and age (r ¼ 0.44 vs
0.36; p ¼ 0.020), hypertension (r ¼ 0.35 vs 0.31; p ¼ 0.044), atrial
ﬁbrillation (r ¼ 0.41 vs 0.31; p < 0.05), previous stroke (r ¼ 0.37 vs
0.21; p ¼ 0.023), glucose blood levels (r ¼ 0.38 vs 0.33; p ¼ 0.023),
LDL cholesterol plasma levels (r ¼ 0.47 vs 0.34; p ¼ 0.012), total
cholesterol plasma levels (r¼ 0.36 vs 0.30; p¼ 0.022), CAD (r¼ 0.29
vs 0.23; p ¼ 0.042), CHF(r ¼ 0.34 vs 0.26; p ¼ 0.039), and LVH
(r ¼ 0.36 vs 0.29; p ¼ 0.021).
4. Discussion
Our study shows that patients with ischemic stroke and meta-
bolic syndrome have higher values of indexes of arterial stiffness in
relation to age, sex and cardiovascular risk factor compared to
control subjects without stroke and also compared to stroke
subjects without metabolic syndrome.
Metabolic syndrome represents a determinant of progressive
arterial stiffening [2,9,10].
At intergroup analysis our ﬁndings show a signiﬁcant difference
among TOAST diagnostic subtypes with regard to arterial stiffness
indexes in subjects with or without metabolic syndrome.We report
that subjects with lacunar subtype and metabolic syndrome show
higher values of PWV and AIx compared to subjects with lacunar
syndrome and without metabolic syndrome. Furthermore subjects
with metabolic syndrome other stroke subtypes (LAAS and CI) also
showed higher values of arterial stiffness indexes compared to
subjects without metabolic syndrome.
Our ﬁndings are consistent with the hypothesis that cerebral
small-vessel disease results from abnormal ﬂow pulsations into the
brain microcirculation as an exposure to highly pulsate pressure
and augmented ﬂow, which exist in the carotid and vertebral
arteries as a result of arterial stiffening, may thus lead to micro-
vascular damage and eventually to stroke [11].
Ischemic stroke is not a homogenous disease and some studies
[12,13] indicate that its patho-physiology differs among the
subtypes of stroke. Moreover, different potentially modiﬁable
vascular risk factor proﬁles were identiﬁed for each subtype of
ischemic stroke, particularly hypertension (and more recently
diabetes) in the case of lacunar infarction. Our study conﬁrmsTa
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previous data regarding the strict association between hyperten-
sion and diabetes and lacunar subtype of stroke, showing a higher
percentage of hypertensive and diabetic subjects in the lacunar
group compared to other subtypes.
So it’s possible that the high prevalence of hypertension in
lacunar stroke subjects may explain the higher values of arterial
stiffness indexes observed in these subjects.
In our patients with acute ischemic stroke and metabolic
syndrome we observed a more signiﬁcant correlation between
hypertension and diabetes and arterial stiffness, particularly in
subjects with lacunar stroke.
On this basis it’s possible to hypothesize that the major
determinants of arterial stiffness and stroke risk in subjects with
metabolic syndrome are hypertension and diabetes. It’s also
possible that the high prevalence of hypertension and diabetes in
lacunar stroke subjects with metabolic syndrome may explain the
higher values of arterial stiffness indexes observed in these
subjects.
It is also plausible that some differences in the relationship
between arterial stiffness indexes and acute ischemia in relation to
the presence of metabolic syndrome could be related to differ-
ences in immune-inﬂammatory activation of the acute phase of
acute ischemia and to each TOAST diagnostic subtype. This is
a very interesting issue and future studies should address this
question.
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.atherosclerosis.2012.08.027.
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